CN109310741A - 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽 - Google Patents

用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽 Download PDF

Info

Publication number
CN109310741A
CN109310741A CN201780038507.8A CN201780038507A CN109310741A CN 109310741 A CN109310741 A CN 109310741A CN 201780038507 A CN201780038507 A CN 201780038507A CN 109310741 A CN109310741 A CN 109310741A
Authority
CN
China
Prior art keywords
peptide
cancer
disease
cell
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780038507.8A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·布莱尼
安东尼·赛拉米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warren Pharmaceuticals Inc
Original Assignee
Warren Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Pharmaceuticals Inc filed Critical Warren Pharmaceuticals Inc
Publication of CN109310741A publication Critical patent/CN109310741A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780038507.8A 2016-04-29 2017-04-28 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽 Pending CN109310741A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329743P 2016-04-29 2016-04-29
US62/329,743 2016-04-29
PCT/US2017/030100 WO2017189988A1 (en) 2016-04-29 2017-04-28 Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Publications (1)

Publication Number Publication Date
CN109310741A true CN109310741A (zh) 2019-02-05

Family

ID=60161215

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780038507.8A Pending CN109310741A (zh) 2016-04-29 2017-04-28 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽

Country Status (5)

Country Link
US (1) US10864253B2 (https=)
EP (1) EP3448415A4 (https=)
JP (1) JP2019523633A (https=)
CN (1) CN109310741A (https=)
WO (1) WO2017189988A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144224A (zh) * 2019-03-26 2022-03-04 保科特纳洛克斯恩公司 药物合成物输送器械和方法
CN114929198A (zh) * 2019-12-13 2022-08-19 麻省理工学院 作为上皮层疗法的聚合物的组织催化生长

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4276105A4 (en) * 2021-01-11 2024-12-18 Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd POLYPEPTIDE FOR REPAIRING A SKIN WOUND OR A MUCOSAL INJURY, AND ITS USE
CN119908970B (zh) * 2025-01-23 2026-02-03 诺德溯源(广州)生物科技有限公司 一种用于改善女性更年期衰老的护肤组合物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193889A (zh) * 1995-06-30 1998-09-23 耶达研究与发展有限公司 用于治疗糖尿病的由人热激蛋白60衍生的新型肽类,其组合物、制法及试剂盒
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
CN101151043A (zh) * 2004-12-21 2008-03-26 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
CN101472606A (zh) * 2006-04-28 2009-07-01 遗传工程与生物技术中心 用于治疗黄病毒感染的方法、分子及用途
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CN102066413A (zh) * 2008-01-22 2011-05-18 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
CA2940078A1 (en) * 2014-03-03 2015-09-11 Centro De Ingenieria Genetica Y Biotecnologia Beta hairpin peptides having anti-viral properties against the dengue virus
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (https=) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
WO2004022577A2 (en) 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005032467A2 (en) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AU2005207891B2 (en) * 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193889A (zh) * 1995-06-30 1998-09-23 耶达研究与发展有限公司 用于治疗糖尿病的由人热激蛋白60衍生的新型肽类,其组合物、制法及试剂盒
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CN101151043A (zh) * 2004-12-21 2008-03-26 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
CN101472606A (zh) * 2006-04-28 2009-07-01 遗传工程与生物技术中心 用于治疗黄病毒感染的方法、分子及用途
CN102066413A (zh) * 2008-01-22 2011-05-18 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CA2940078A1 (en) * 2014-03-03 2015-09-11 Centro De Ingenieria Genetica Y Biotecnologia Beta hairpin peptides having anti-viral properties against the dengue virus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144224A (zh) * 2019-03-26 2022-03-04 保科特纳洛克斯恩公司 药物合成物输送器械和方法
CN114929198A (zh) * 2019-12-13 2022-08-19 麻省理工学院 作为上皮层疗法的聚合物的组织催化生长

Also Published As

Publication number Publication date
WO2017189988A8 (en) 2018-01-25
EP3448415A1 (en) 2019-03-06
EP3448415A4 (en) 2019-11-06
JP2019523633A (ja) 2019-08-29
US20190134156A1 (en) 2019-05-09
US10864253B2 (en) 2020-12-15
WO2017189988A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
KR101768792B1 (ko) 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
JP2021090447A (ja) 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
CN109310741A (zh) 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190205